The University of California, Los Angeles'Jonsson Comprehensive Cancer Center (JCCC) is an NCI designated matrix center conducting a wide range of translational research in the areas of laboratory, clinical and population sciences integrating the activities of 244 members. Based on the JCCC Strategic Plan, the goals of the JCCC are the integration of clinical activities to provide patient-centered care;research infrastructure improvement through technology and shared resources;increased communication within JCCC and to our many audiences;faculty support and development at all levels;and the advancement of emerging areas of research. Over the past funding cycle 70% of patients enrolled in interventional clinical trials participated in investigator-initiated studies. The tota funding base for the JCCC is $163 million with $40 million in NCI funding. Our NCI funding includes subcontracts from other institutions, of which a significant amount is derived from our partnership with California Institute of Technology. In addition, of 3,489 total publications in th reporting period, 35% were published in high-impact journals, 15% were inter-programmatic and 21% were intra-programmatic. Continuing support is requested for the following eight Programs Areas and six Shared Resources. Programs: Cancer and Stem Cell Biology*, Cancer Molecular Imaging, Cancer Nanotechnology*, Gene Regulation, Healthy and At-Risk Populations, Patients and Survivors, Signal Transduction and Therapeutics, Tumor Immunology. (*New Program Area) Shared Resources: Biostatistics, Analytical Support &Evaluation, Genomics, Flow Cytometry, Translational Pathology, Molecular Screening Shared Resource, Small Animal Imaging Shared Resource

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016042-39S2
Application #
8918237
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-09-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$308,000
Indirect Cost
$108,000
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395
Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93

Showing the most recent 10 out of 767 publications